High SCA Treatment Rates Despite Contemporary GDMT in 19,000+ Consecutive LifeVest® Patient Study
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced results from SCD-PROTECT, a nationwide analysis of LifeVest® wearable cardioverter defibrillator (WCD) patients in Germany, presented on May 18, 2025 as a late-breaking clinical trial at the European Society of Cardiology (ESC) Heart Failure 2025 conference.
Survey Reveals Critical Gap: 90% of Americans Want You—the Bystander—to Use an AED to Help Save Their Life in a Cardiac Emergency, But Less Than Half Believe They Have Same Responsibility. Many Still Don’t Know AEDs Offer Step-By-Step Instructions
In advance of National Heart Health Month, and on the heels of the milestone passing of the HEARTS Act, ZOLL® Medical’s Anything Can Happen. Anyone Can Help.™ education campaign is releasing results from a national survey* of more than 2,000 American adults that reveals a concerning gap in awareness and understanding about the role AEDs play in a cardiac emergency. Insufficient awareness may leave bystanders hesitant to act in a crisis, and highlights the urgent need to educate the public on the ease and importance of using an AED.
ZOLL Enrolls First Patient in Groundbreaking SSCORE Commercial Registry at Minneapolis Heart Institute at Abbott Northwestern Hospital (Minneapolis, MN)
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the first patient has been enrolled in the SuperSaturated oxygen Comprehensive Observational REgistry (SSCORE). The prospective study is designed to provide further evidence of the efficacy of SuperSaturated Oxygen (SSO2) Therapy to reduce heart failure and mortality in patients suffering from left anterior descending ST-elevation myocardial infarction (LAD STEMI) heart attacks, the most serious type of heart attack. LAD STEMI heart attacks are often referred to as “widow makers” due to the high mortality rate associated with this condition. Additionally, SSCORE will collect data to substantiate the potential improvement in overall healthcare costs associated with prevention of heart failure versus a lifetime of palliative treatment strategies.
ZOLL Receives Innovative Technology Contract from Vizient for TherOx SuperSaturated Oxygen (SSO2) Therapy
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it has received an Innovative Technology contract from Vizient, Inc., the nation’s largest provider-driven healthcare performance improvement company. The contract was awarded based on the recommendation of hospital experts who serve on one of Vizient’s customer-led councils, and it signifies unique qualities that potentially bring improvement to patient cardiovascular care.
ZOLL Reports Email Phishing Attack
ZOLL Medical Corporation (“ZOLL”) is notifying individuals who were in contact with ZOLL Respicardia either directly or indirectly through a provider, or whose provider contacted ZOLL Respicardia on their behalf, that their health information may have been accessed by an unauthorized party after a ZOLL employee was the victim of a sophisticated email phishing attack. This incident was limited to emails and had no impact on ZOLL’s medical devices, software, or services. The information affected by the incident may have included some individuals’ names and health information. ZOLL has no indication that the information has been misused. ZOLL is evaluating its cybersecurity education and training measures for employees. Individuals with questions can contact a dedicated call center at 800-459-4255 Monday through Friday from 8 a.m. to 8 p.m. CST, closed Saturday and Sunday (and excluding major U.S. holidays).
ZOLL Expands Temperature Management Portfolio to Include IQool™ System, High-Quality Surface Option
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it has entered into an agreement with BrainCool, a medical device company specializing in temperature management solutions, for the exclusive distribution of the BrainCool™ System/IQool™ System and the IQool™ System Pads in the U.S. and key markets in Europe, and are working towards expanding distribution to select markets in Asia.
ZOLL remedē System, a Breakthrough Therapy for Treating Central Sleep Apnea, Receives Approval for MRI Conditional Use
ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the United States Food and Drug Administration (FDA) has approved the remedē System for conditional use with magnetic resonance imaging (MRI). ZOLL’s remedē System is an implantable transvenous phrenic nerve stimulation therapy for the treatment of adults with moderate to severe Central Sleep Apnea (CSA). Full-body MRI approval applies to all models of remedē System, covering new remedē patients as well as those who already have a remedē device.
Results from Benefit of Microcor in Acute Decompensated Heart Failure (BMAD) Trial Presented as ACC.23/WCC Late-Breaking Clinical Trial
ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that results from the Benefit of Microcore in Acute Decompensated Heart Failure (BMAD) Trial were presented today by Dr. John Boehmer, MD, of Penn State Health Milton S. Hershey Medical Center and the trial lead investigator, as a Late-Breaking Clinical Trial at the American College of Cardiology’s 72nd Annual Scientific Session Together with World Congress of Cardiology.
First Patient Enrolled in AMIHOT III Trial Investigating ZOLL’s Supersaturated Oxygen Therapy in Heart Attack Patients
ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the first patient has enrolled in the AMIHOT III post-approval study further evaluating TherOx® SuperSaturated Oxygen (SSO2) Therapy for the treatment of the most severe form of heart attack, left anterior descending (LAD) ST-Elevation Myocardial Infarction (STEMI). The patient, treated at WakeMed Health & Hospitals in North Carolina, received SSO2 Therapy, the first FDA-approved therapy shown to significantly reduce the size of damaged tissue (infarct) following percutaneous coronary intervention (PCI).
Centers for Medicare & Medicaid Services (CMS) Issue New ICD-10-PCS Code for ZOLL Medical's TherOx SSO2 Therapy
ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the Centers for Medicare & Medicaid Services (CMS) ICD-10 Coordination and Maintenance Committee has issued a new ICD-10-PCS code for TherOx® SuperSaturated Oxygen (SSO2) Therapy. The new code (5A0222C), for cardiac intra-arterial use, is effective for hospital discharges beginning October 1, 2022. The code includes treatment of patients with left anterior descending ST-elevation myocardial infarction (LAD STEMI) heart attacks, which have higher mortality rates than other types of heart attacks. SSO2 Therapy is the first and only FDA-approved treatment that has been clinically proven to significantly reduce damage to cardiac muscle in heart attack patients after coronary angioplasty with stenting.1
ZOLL Launches Next Generation MCT Solution, Shown to Improve Patient Management Decisions in Largest Ever MCT Trial
ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced the launch of the ZOLL Arrhythmia Management System (AMS). ZOLL AMS adds biometric data (heart rate, activity, respiratory rate, and body posture) to the ECG information provided by traditional MCT devices. A new study demonstrates that ZOLL AMS helps physicians make more informed patient treatment plans.
ZOLL Announces Closing of Acquisition of Itamar Medical
ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced that it has successfully completed its previously announced acquisition of Itamar™ Medical Ltd. (Nasdaq and TASE: ITMR) (“Itamar Medical”), a medical device and digital health company that provides at-home testing for sleep apnea.
ZOLL’s TherOx SuperSaturated Oxygen Therapy to Be Highlighted at SCAI Shock Virtual Conference
ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that its TherOx® SuperSaturated Oxygen (SSO2) Therapy will be the focus of a panel discussion at the upcoming Society for Cardiovascular Angiography & Interventions (SCAI) Shock virtual conference October 7-8.
ZOLL Medical Corporation Signs Definitive Agreement to Acquire Itamar Medical
ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, and Itamar™ Medical Ltd. (Nasdaq and TASE: ITMR), a medical device and digital health company focused on the integration of sleep apnea diagnosis into the cardiac patient care pathway, today announced that the two companies signed a definitive agreement under which ZOLL Medical will acquire all outstanding ordinary shares of Itamar Medical for a total value of approximately $538 million.
American Medical Association Issues New Category III CPT Code for ZOLL Medical’s TherOx SSO2 Therapy
ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the American Medical Association (AMA) CPT Editorial Panel issued a new Category III CPT® code, effective July 1, 2021, for its TherOx® SuperSaturated Oxygen (SSO2) Therapy. The code, 0659T (transcatheter intracoronary infusion of supersaturated oxygen in conjunction with percutaneous coronary revascularization during acute myocardial infarction, including catheter placement, imaging guidance [e.g., fluoroscopy], angiography, and radiologic supervision and interpretation), is effective July 1, 2021 for SSO2 Therapy including treatment of patients with left anterior descending ST-elevation myocardial infarction (LAD STEMI) heart attacks. SSO2 Therapy is the first and only FDA-approved treatment that has been clinically proven to significantly reduce cardiac muscle damage in heart attack patients after coronary angioplasty with stenting.1
ZOLL Announces Approval of Next-Generation remedē System for the Treatment of Central Sleep Apnea (Transvenous Phrenic Nerve Stimulation)
ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it has received U.S. Food and Drug Administration (FDA) approval for the remedē® EL-X System to treat moderate to severe Central Sleep Apnea (CSA) in adult patients.1 CSA is a serious condition that is often associated with heart failure, coronary artery disease, and certain cardiac arrhythmias.
ZOLL Accelerates EMS Participation in New York State Data Exchange Incentive Program
ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that its Data Systems division has helped more than 60 emergency medical service (EMS) agencies in New York state improve patient safety by adopting ZOLL Care Exchange. ZOLL Data Systems’ technology enables EMS agencies to exchange information in real time with partner hospitals to enhance continuity of care in emergent situations when every second counts.
